Geoff Meacham
Stock Analyst at Citigroup
(4.28)
# 428
Out of 5,150 analysts
289
Total ratings
60.66%
Success rate
11.83%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Maintains: Buy | $55 → $58 | $46.32 | +25.22% | 2 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $110 → $120 | $82.49 | +45.47% | 8 | Mar 2, 2026 | |
| MANE Veradermics | Initiates: Buy | $85 | $48.95 | +73.65% | 1 | Mar 2, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $110 → $115 | $114.29 | +0.62% | 2 | Feb 24, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $15 → $19 | $13.96 | +36.10% | 6 | Feb 20, 2026 | |
| BIIB Biogen | Maintains: Neutral | $185 → $215 | $186.69 | +15.16% | 19 | Feb 9, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $64 | $60.68 | +5.47% | 9 | Feb 6, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $115 → $120 | $115.72 | +3.70% | 11 | Feb 4, 2026 | |
| AMGN Amgen | Maintains: Neutral | $315 → $345 | $363.72 | -5.15% | 14 | Feb 4, 2026 | |
| ABBV AbbVie | Maintains: Neutral | $235 → $230 | $229.90 | +0.04% | 22 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $156 | $144.67 | +7.83% | 9 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $50 | $45.51 | +9.87% | 4 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $14.31 | +249.41% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $115 | $91.19 | +26.11% | 4 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $49 | $13.79 | +255.33% | 3 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $26 | $26.50 | -1.89% | 7 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $3.30 | +142.42% | 6 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $75 | $62.69 | +19.65% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $700 | $765.26 | -8.53% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $28 | $52.40 | -46.56% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $30.34 | +64.80% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $50 | $45.43 | +10.06% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $93 | $56.80 | +63.73% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $575 | $463.35 | +24.10% | 6 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $14 | $9.15 | +53.01% | 3 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $54 | $65.55 | -17.62% | 6 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $6 | $9.56 | -37.24% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $140 | $99.80 | +40.28% | 2 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $1 | $2.98 | -66.44% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $95 | $69.35 | +36.99% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $103 | $60.51 | +70.22% | 3 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $1.74 | +129.89% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $970.91 | +13.30% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $120 → $20 | $22.11 | -9.54% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $34.11 | -9.12% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $236.23 | -28.04% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $1.30 | +1,207.69% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $1.71 | +1,303.51% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $11.49 | -65.19% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $15.34 | +82.53% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.61 | +1,205.18% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $2.81 | +1,145.55% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $525 | $29.81 | +1,661.15% | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.53 | +2,645.10% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $6.82 | +193.26% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $0.38 | +5,150.72% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $6.22 | +44.69% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $8.56 | +600.93% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $24.72 | -6.96% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $97.37 | -15.79% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $487.84 | -80.53% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $21.65 | +269.52% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $130.70 | +3.29% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.60 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $3.60 | +456.33% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $10.37 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $324.94 | -51.38% | 5 | Nov 8, 2017 |
Scholar Rock Holding
Mar 4, 2026
Maintains: Buy
Price Target: $55 → $58
Current: $46.32
Upside: +25.22%
Kymera Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $110 → $120
Current: $82.49
Upside: +45.47%
Veradermics
Mar 2, 2026
Initiates: Buy
Price Target: $85
Current: $48.95
Upside: +73.65%
Arcellx
Feb 24, 2026
Downgrades: Neutral
Price Target: $110 → $115
Current: $114.29
Upside: +0.62%
Amylyx Pharmaceuticals
Feb 20, 2026
Maintains: Buy
Price Target: $15 → $19
Current: $13.96
Upside: +36.10%
Biogen
Feb 9, 2026
Maintains: Neutral
Price Target: $185 → $215
Current: $186.69
Upside: +15.16%
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Neutral
Price Target: $60 → $64
Current: $60.68
Upside: +5.47%
Merck & Co.
Feb 4, 2026
Maintains: Neutral
Price Target: $115 → $120
Current: $115.72
Upside: +3.70%
Amgen
Feb 4, 2026
Maintains: Neutral
Price Target: $315 → $345
Current: $363.72
Upside: -5.15%
AbbVie
Jan 27, 2026
Maintains: Neutral
Price Target: $235 → $230
Current: $229.90
Upside: +0.04%
Jan 27, 2026
Maintains: Buy
Price Target: $140 → $156
Current: $144.67
Upside: +7.83%
Jan 27, 2026
Maintains: Buy
Price Target: $48 → $50
Current: $45.51
Upside: +9.87%
Jan 9, 2026
Initiates: Buy
Price Target: $50
Current: $14.31
Upside: +249.41%
Dec 8, 2025
Maintains: Buy
Price Target: $98 → $115
Current: $91.19
Upside: +26.11%
Dec 2, 2025
Maintains: Buy
Price Target: $58 → $49
Current: $13.79
Upside: +255.33%
Dec 2, 2025
Reinstates: Neutral
Price Target: $26
Current: $26.50
Upside: -1.89%
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $3.30
Upside: +142.42%
Nov 5, 2025
Maintains: Neutral
Price Target: $50 → $75
Current: $62.69
Upside: +19.65%
Oct 29, 2025
Maintains: Buy
Price Target: $660 → $700
Current: $765.26
Upside: -8.53%
Oct 23, 2025
Maintains: Neutral
Price Target: $30 → $28
Current: $52.40
Upside: -46.56%
Oct 17, 2025
Maintains: Buy
Price Target: $42 → $50
Current: $30.34
Upside: +64.80%
Oct 17, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $45.43
Upside: +10.06%
Oct 17, 2025
Maintains: Buy
Price Target: $78 → $93
Current: $56.80
Upside: +63.73%
Oct 2, 2025
Maintains: Buy
Price Target: $550 → $575
Current: $463.35
Upside: +24.10%
Aug 27, 2025
Upgrades: Buy
Price Target: $12 → $14
Current: $9.15
Upside: +53.01%
Jun 25, 2025
Maintains: Buy
Price Target: $50 → $54
Current: $65.55
Upside: -17.62%
Jun 17, 2025
Initiates: Sell
Price Target: $6
Current: $9.56
Upside: -37.24%
May 6, 2025
Maintains: Buy
Price Target: $145 → $140
Current: $99.80
Upside: +40.28%
Apr 2, 2025
Downgrades: Underperform
Price Target: $7 → $1
Current: $2.98
Upside: -66.44%
Mar 13, 2025
Initiates: Buy
Price Target: $95
Current: $69.35
Upside: +36.99%
Feb 20, 2025
Maintains: Buy
Price Target: $99 → $103
Current: $60.51
Upside: +70.22%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $1.74
Upside: +129.89%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $970.91
Upside: +13.30%
Oct 30, 2024
Downgrades: Underperform
Price Target: $120 → $20
Current: $22.11
Upside: -9.54%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $34.11
Upside: -9.12%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $236.23
Upside: -28.04%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $1.30
Upside: +1,207.69%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $1.71
Upside: +1,303.51%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $11.49
Upside: -65.19%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $15.34
Upside: +82.53%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $2.61
Upside: +1,205.18%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $2.81
Upside: +1,145.55%
Nov 23, 2020
Initiates: Buy
Price Target: $525
Current: $29.81
Upside: +1,661.15%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.53
Upside: +2,645.10%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $6.82
Upside: +193.26%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $0.38
Upside: +5,150.72%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $6.22
Upside: +44.69%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $8.56
Upside: +600.93%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $24.72
Upside: -6.96%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $97.37
Upside: -15.79%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $487.84
Upside: -80.53%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $21.65
Upside: +269.52%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $130.70
Upside: +3.29%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $9.60
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $3.60
Upside: +456.33%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $10.37
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $324.94
Upside: -51.38%